Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BRN022
MIFTS: 60

Bronchiectasis

Categories: Genetic diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bronchiectasis

About this section

MalaCards integrated aliases for Bronchiectasis:

Name: Bronchiectasis 12 74 29 54 6 44 15 62 71 32
Polynesian Bronchiectasis 12
Kartagener Syndrome 71

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9563
ICD9CM 34 494
MeSH 44 D001987
NCIt 50 C84475
SNOMED-CT 67 155580000
ICD10 32 J47
UMLS 71 C0006267 C0022521
Sources

Summaries for Bronchiectasis

About this section
PubMed Health : 62 About bronchiectasis: Bronchiectasis (brong-ke-EK-tah-sis) is a condition in which damage to the airways causes them to widen and become flabby and scarred. The airways are tubes that carry air in and out of your lungs. Bronchiectasis often is caused by an infection or other condition that injures the walls of the airways or prevents the airways from clearing mucus. Mucus is a slimy substance. It helps remove inhaled dust, bacteria, and other small particles from the airways. In bronchiectasis, your airways slowly lose their ability to clear out mucus. The mucus builds up, and bacteria begin to grow. This leads to repeated, serious lung infections. Each infection causes more damage to the airways. Over time, the airways can't properly move air in and out of the lungs. As a result, the body's vital organs might not get enough oxygen. Bronchiectasis can lead to serious health problems, such as respiratory failure, atelectasis (at-eh-LEK-tah-sis), and heart failure.

MalaCards based summary : Bronchiectasis, also known as polynesian bronchiectasis, is related to idiopathic bronchiectasis and bronchiectasis with or without elevated sweat chloride 1, and has symptoms including headache An important gene associated with Bronchiectasis is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Tobramycin and Meropenem have been mentioned in the context of this disorder. Affiliated tissues include lung, neutrophil and trachea, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A bronchial disease that is a chronic inflammatory condition of one or more bronchi or bronchioles marked by dilatation and loss of elasticity of the walls resulting from damage to the airway wall leading to the formation of small sacs on the bronchial wall and impairment of cilia mobility in the lung. Inflammation of the bronchial wall increases mucus secretion which serves as a breeding ground for bacteria. Bronchiectasis is caused by repeated respiratory infections, immune deficiency disorders, hereditary disorders (cystic fibrosis or primary ciliary dyskinesia), mechanical factors (inhaled object or a lung tumor) or inhaling toxic substances.

Wikipedia : 74 Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung.... more...

Sources

Related Diseases for Bronchiectasis

About this section

Diseases in the Bronchiectasis family:

Bronchiectasis 1 Bronchiectasis 2
Bronchiectasis 3

Diseases related to Bronchiectasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 690)
# Related Disease Score Top Affiliating Genes
1 idiopathic bronchiectasis 32.5 SCNN1G SCNN1B SCNN1A CFTR
2 bronchiectasis with or without elevated sweat chloride 1 32.0 USP11 STAT1 SCNN1B CFTR
3 nontuberculous mycobacterial lung disease 31.8 TNF TLR2 CFTR
4 primary ciliary dyskinesia 31.7 USP11 SERPINA1 MBL2 ELANE DNAI1 DNAH5
5 bronchial disease 31.5 TNF TLR2 SERPINA3 ELANE CXCL8 CFTR
6 haemophilus influenzae 31.5 TNF TLR2 CXCL8
7 bronchiolitis 31.2 TNF TLR2 CXCL8
8 aspergillosis 31.1 TNF TLR2 MBL2 ELANE CXCL8 CFTR
9 pulmonary tuberculosis 31.1 TNF TLR2 MBL2
10 gastroesophageal reflux 31.0 TNF MPO ELANE CXCL8
11 cystic fibrosis 30.7 TNF TLR2 SLPI SERPINA1 SCNN1G SCNN1B
12 common variable immunodeficiency 30.7 TNF TLR2 SERPINA1 MPO MBL2
13 respiratory failure 30.7 TNF SERPINA3 SERPINA1 MPO MMP8 ELANE
14 ulcerative colitis 30.6 TNF MPO CXCL8 CTSG BPI
15 mycobacterium abscessus 30.6 TNF TLR2 SERPINA1 CXCL8 CFTR
16 pleurisy 30.5 TNF TLR2 MPO CXCL8
17 diarrhea 30.5 TNF SERPINA1 MPO CXCL8 CFTR
18 endophthalmitis 30.5 TNF TLR2 CXCL8
19 bronchiolitis obliterans 30.5 TNF SLPI MPO MMP8 CXCL8
20 otitis media 30.4 TNF TLR2 MPO MBL2 CXCL8
21 disease by infectious agent 30.4 TNF TLR2 SERPINA3 SERPINA1 MBL2 CFTR
22 glomerulonephritis 30.4 MPO MBL2 ELANE CTSG
23 bronchopneumonia 30.4 TNF SERPINA3 MPO ELANE CXCL8
24 rheumatoid arthritis 30.4 TNF TLR2 MPO MMP8 MBL2 ELANE
25 pulmonary fibrosis, idiopathic 30.4 TNF SERPINA1 MPO MMP8 ELANE CXCL8
26 extrinsic allergic alveolitis 30.4 MPO ELANE CXCL8
27 alpha-1-antitrypsin deficiency 30.3 TNF SLPI SERPINA3 SERPINA1 MPO ELANE
28 pulmonary edema 30.3 TNF CXCL8 CFTR
29 mycobacterium kansasii 30.3 TLR2 CXCL8
30 bacterial infectious disease 30.3 TNF TLR2 SERPINA3 MBL2 ELANE CXCL8
31 anca-associated vasculitis 30.3 SERPINA1 MPO
32 pulmonary disease, chronic obstructive 30.3 TNF TLR2 SLPI SERPINA3 SERPINA1 MPO
33 klebsiella pneumonia 30.2 TNF TLR2 CXCL8
34 pneumoconiosis 30.2 TNF SERPINA1 CXCL8
35 cholangitis 30.2 TNF MPO CXCL8 CFTR
36 sclerosing cholangitis 30.2 TNF MPO CXCL8 CFTR
37 crescentic glomerulonephritis 30.2 MPO CTSG BPI
38 vasculitis 30.2 TNF SERPINA3 SERPINA1 MPO MBL2 ELANE
39 pulmonary emphysema 30.2 SLPI SERPINA3 SERPINA1 MMP8 ELANE CXCL8
40 mycobacterium chelonae 30.1 TLR2 CXCL8
41 bronchitis 30.1 TNF TLR2 STAT1 SLPI SERPINA1 MPO
42 lung disease 30.1 TNF TLR2 SLPI SERPINA3 SERPINA1 MPO
43 mycobacterium tuberculosis 1 30.1 TNF TLR2 STAT1 SERPINA3 MBL2
44 common cold 30.1 TNF CXCL8 CFTR
45 adult respiratory distress syndrome 30.0 TNF MPO ELANE CXCL8 CTSG
46 chlamydia pneumonia 30.0 TNF TLR2 CXCL8
47 churg-strauss syndrome 30.0 TNF MPO CXCL8
48 crohn's disease 30.0 TNF TLR2 MPO CXCL8
49 streptococcus pneumonia 30.0 TNF TLR2 CXCL8
50 hypersensitivity vasculitis 30.0 TNF SERPINA3 MPO

Comorbidity relations with Bronchiectasis via Phenotypic Disease Network (PDN): (show all 20)


Agammaglobulinemia, X-Linked Anxiety
Aspergillosis Bronchitis
Bronchopneumonia Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Idiopathic Interstitial Pneumonia
Lung Abscess Mitral Valve Disease
Osteoporosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Pulmonary Tuberculosis
Respiratory Failure Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Bronchiectasis:



Diseases related to Bronchiectasis
Sources

Symptoms & Phenotypes for Bronchiectasis

About this section

UMLS symptoms related to Bronchiectasis:


headache

MGI Mouse Phenotypes related to Bronchiectasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 CFTR ELANE MBL2 MMP8 MPO SCNN1A
2 hematopoietic system MP:0005397 10.18 CFTR CTSG DNAH5 DNAI1 ELANE MBL2
3 mortality/aging MP:0010768 10.13 CFTR CTSG DNAH5 DNAI1 ELANE MPO
4 immune system MP:0005387 10.1 CFTR CTSG DNAH5 DNAI1 ELANE MBL2
5 digestive/alimentary MP:0005381 10.03 CFTR DNAH5 SCNN1A SCNN1B SCNN1G STAT1
6 neoplasm MP:0002006 9.7 CTSG ELANE MMP8 STAT1 TLR2 TNF
7 normal MP:0002873 9.65 CFTR CTSG DNAI1 ELANE SCNN1A SCNN1B
8 respiratory system MP:0005388 9.28 CFTR DNAH5 DNAI1 SCNN1A SCNN1B SCNN1G
Sources

Drugs & Therapeutics for Bronchiectasis

About this section

PubMed Health treatment related to Bronchiectasis: 62

Bronchiectasis often is treated with medicines, hydration , and chest physical therapy (CPT). Your doctor may recommend surgery if the bronchiectasis is isolated to a section of lung or you have a lot of bleeding . If the bronchiectasis is widespread and causing respiratory failure , your doctor may recommend oxygen therapy . The goals of treatment are to: Treat any underlying conditions and lung infections. Remove mucus (a slimy substance) from your lungs . Maintaining good hydration helps with mucus removal. Prevent complications. Early diagnosis and treatment of the underlying cause of bronchiectasis may help prevent further lung damage. In addition, any disease associated with the bronchiectasis , such as cystic fibrosis or immunodeficiency, also should be treated.

Drugs for Bronchiectasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
2
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
3
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
4
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Theophylline Approved Phase 4 58-55-9 2153
7
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
8
Budesonide Approved Phase 4 51333-22-3 63006 5281004
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
11 Calciferol Phase 4
12 Nutrients Phase 4
13 Micronutrients Phase 4
14 Trace Elements Phase 4
15 Calcium, Dietary Phase 4
16 Immunologic Factors Phase 4
17 Gentamicins Phase 4
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
19 Hypolipidemic Agents Phase 4
20 Antimetabolites Phase 4
21 Lipid Regulating Agents Phase 4
22 Anticholesteremic Agents Phase 4
23
Salmeterol xinafoate Phase 4 94749-08-3 56801
24 Sympathomimetics Phase 4
25 Fluticasone-Salmeterol Drug Combination Phase 4
26 Adjuvants, Immunologic Phase 4
27 Broncho-Vaxom Phase 4
28 Phosphodiesterase Inhibitors Phase 4
29 Astragalus Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Hormones Phase 4
32 Adrenergic beta-Agonists Phase 4
33 Neurotransmitter Agents Phase 4
34 Adrenergic Agonists Phase 4
35 Hormone Antagonists Phase 4
36 Formoterol Fumarate Phase 4
37 glucocorticoids Phase 4
38 Adrenergic Agents Phase 4
39 Parasympatholytics Phase 4
40 Anticonvulsants Phase 4
41 Cholinergic Antagonists Phase 4
42 Tiotropium Bromide Phase 4 136310-93-5
43 Bromides Phase 4
44 Budesonide, Formoterol Fumarate Drug Combination Phase 4
45 Cholinergic Agents Phase 4
46 Expectorants Phase 4
47 Respiratory System Agents Phase 4
48 Anti-Asthmatic Agents Phase 4
49 Bronchodilator Agents Phase 4
50 Immunoglobulins Phase 4

Interventional clinical trials:

(show top 50) (show all 241)
# Name Status NCT ID Phase Drugs
1 The Study on the Effects of Traditional Chinese Medicine Through a Series of N-of-1 Trials Based on the Mathematical Model of "Carryover Effect" Unknown status NCT03147443 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
2 Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis: a Double-blind Randomised Controlled Trial Unknown status NCT02507843 Phase 4 Cholecalciferol;Placebo
3 Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis:An Open-label Randomized Parallel Controlled Study Unknown status NCT02509091 Phase 4 Bronchoalveolar Lavage and Local Amikacin Injection
4 A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis Unknown status NCT01677403 Phase 4 Tobramycin;Saline
5 Bacterial Load Guided Therapy for Severe Exacerbations of Bronchiectasis Requiring IntraVenous Antibiotic Therapy- BLT Br IV Study Completed NCT02047773 Phase 4 Colomycin;Meropenem
6 Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Completed NCT00816309 Phase 4
7 A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Completed NCT02081963 Phase 4 Amikacin;Normal saline
8 Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis Completed NCT00749866 Phase 4 Gentamicin;Saline
9 A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Completed NCT01299181 Phase 4 Atorvastatin
10 Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis With Airway Limitation: a Prospective Study Completed NCT02782312 Phase 4 ICS+LABA
11 To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients Completed NCT01968421 Phase 4 OM-85 BV
12 The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Completed NCT01769898 Phase 4 Formoterol-budesonide;Theophylline;Placebo
13 A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in Patients With Pseudomonas Aeruginosa Completed NCT01299194 Phase 4 ATORVASTATIN
14 Efficacy of Azithromycin in Treatment of Bronchiectasis Completed NCT02107274 Phase 4 Azithromycin;Placebo for Azithromycin
15 Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Completed NCT00868075 Phase 4
16 Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis Completed NCT01684683 Phase 4 Theophylline;Placebo(for Theophylline)
17 A Series of N-of-1 Trials on Bronchiectasis Treated With Traditional Chinese Medicine Based on Bayesian Model Recruiting NCT04601792 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
18 The Comparisons of the Efficacy and Safety of Inhaled LAMA or LAMA+LABA or ICS+LABA for Patients in COPD C Group With Bronchiectasis Enrolling by invitation NCT02546297 Phase 4 Symbicort;Spiriva
19 Efficacy and Safety of An'Ningpai Enteric Soft Capsuleson in Stable Non-CF Bronchiectasis With Hypersecretion: a Open-label Randomized Controlled Trial Not yet recruiting NCT04511897 Phase 4 An'ningpai
20 Efficacy and Safety of Inhaled Bronchodilator in Non-cystic Fibrosis Bronchiectasis Patients With Airflow Limitation: a Multicenter, Open-label Randomized Controlled Trial Not yet recruiting NCT04509661 Phase 4 LABA/LAMA or Placebo inhalation
21 Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study Suspended NCT03737617 Phase 4 Cuvitru 20 % Injectable Solution
22 Effects of Traditional Chinese Medicine on Bronchiectasis Patients: A Multi-center, Randomized, Double-blind, Controlled Trial Unknown status NCT03443531 Phase 3 Bufei Huatan granule;Yifei Qinghua granule;Placebo Bufei Huatan granule;Placebo Yifei Qinghua granule
23 Open Trial With Randomized Withdrawal of Treatment, to Evaluate the Efficacy of Azithromycin in the Treatment of Children With Non Cystic Fibrosis Bronchiectasis ( AZI-STOP Study ) Unknown status NCT02531984 Phase 3 Azithromycin
24 Formoterol-beclomethasone in Patients With Bronchiectasis: a Randomized Controlled Trial Unknown status NCT03846570 Phase 3 Formoterol-beclomethasone;Placebo
25 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study Completed NCT00380315 Phase 3 AG1321001(drug)
26 Long-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy. Completed NCT02657473 Phase 2, Phase 3 tobramycin inhalation solution;Saline 0.9% inhalation solution
27 The Role of Vitamin D3 in Pediatric Bronchiectasis Severity( CF Versus Non CF Bronchioectasis) Completed NCT04411901 Phase 2, Phase 3 Cholecalciferol (vitaminD3)
28 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection Completed NCT01313624 Phase 3 AZLI;Placebo
29 A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis. Completed NCT00277537 Phase 3 Mannitol;placebo
30 Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis. Completed NCT02106832 Phase 3 Ciprofloxacin (BAYQ3939) dry powder for inhalation;Ciprofloxacin (BAYQ3939) dry powder for inhalation;Placebo;Placebo
31 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension Completed NCT02104245 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
32 Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis. Completed NCT01764841 Phase 3 Ciprofloxacin DPI (BAYQ3939);Placebo
33 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2) Completed NCT01314716 Phase 3 AZLI;Placebo
34 Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment Completed NCT00415350 Phase 3 Azithromycin
35 : A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis. Completed NCT00669331 Phase 3 Inhaled mannitol;Matched control
36 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3) Completed NCT01515007 Phase 3 Ciprofloxacin dispersion for inhalation;Placebo
37 "A Prospective, Cross-over Randomized Trial to Assess the Efficacy and Safety of Mechanical Percussor "LEGA" Compared With Conventional Chest Physiotherapy in Adults With Chronic Bronchiectasis or Chronic Obstructive Pulmonary Disease (COPD Completed NCT01480882 Phase 2, Phase 3
38 The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis. Completed NCT00484263 Phase 3 Hypertonic saline 6% -
39 Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis: a Randomized Double-blind Placebo-controlled Trial Completed NCT04122547 Phase 3 Roflumilast;Placebo
40 Effects of Roxithromycin on Quality of Life and Physiologic Outcomes in Bronchiectasis Patients During Treatment and Posttreatment Period Completed NCT04122040 Phase 3 Roxithromycin 300 MG;Placebo
41 A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) Completed NCT00105183 Phase 3
42 Efficacy and Safety of Inhaled Tobramycin on Bronchiectasis Colonized With Pseudomonas Aeruginosa: A Randomized, Double-blind, Parallel-group Multicenter Trial Recruiting NCT03715322 Phase 3 Tobramycin Inhalant Product;Natural saline inhalation
43 A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa) Recruiting NCT03460704 Phase 3 Colistimethate sodium;Saline Solution
44 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study Recruiting NCT04594369 Phase 3 Brensocatib 10 mg;Brensocatib 25 mg;Placebo
45 A 2x2 Factorial Randomized Open Label Trial to Determine the Clinical and Cost-effectiveness of Hypertonic Saline (HTS) 6% and Carbocisteine for Airway Clearance Versus Usual Care Over 52 Weeks in Bronchiectasis Recruiting NCT04140214 Phase 3 Hypertonic saline;Carbocysteine 750 MG
46 Study of RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease (CleaR-MAC Trial) Recruiting NCT04616924 Phase 3 RHB-204;Placebo
47 A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis. Active, not recruiting NCT01270074 Phase 3 Azithromycin;Placebo control
48 A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa) Active, not recruiting NCT03093974 Phase 3 Colistimethate Sodium;Saline Solution
49 Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound Terminated NCT03829618 Phase 3 Topical lidocaine;Nebuliser solution;Nebuliser Suspension
50 A Randomised Double Blind 13 Week Crossover Trial of Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Patients With Bronchiectasis. Unknown status NCT01112410 Phase 2

Search NIH Clinical Center for Bronchiectasis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Acetylcysteine

Cochrane evidence based reviews: bronchiectasis

Sources

Genetic Tests for Bronchiectasis

About this section

Genetic tests related to Bronchiectasis:

# Genetic test Affiliating Genes
1 Bronchiectasis 29
Sources

Anatomical Context for Bronchiectasis

About this section

MalaCards organs/tissues related to Bronchiectasis:

40
Lung, Neutrophil, Trachea, Bone Marrow, Thyroid, Lymph Node, B Cells
Sources

Publications for Bronchiectasis

About this section

Articles related to Bronchiectasis:

(show top 50) (show all 9589)
# Title Authors PMID Year
1
Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. 61 54
20167849 2010
2
Allergic bronchopulmonary aspergillosis. 54 61
20463254 2010
3
Novel cftr gene sequence variation in Serbian patient with idiopathic disseminated bronchiectasis. 54 61
20334484 2010
4
Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. 54 61
19616787 2009
5
Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. 61 54
19555716 2009
6
Stable bronchiectasis is associated with low serum L-ficolin concentrations. 61 54
20298369 2009
7
Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis. 61 54
19138237 2008
8
Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. 54 61
18978467 2008
9
TLR expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. 61 54
18684966 2008
10
Could a defective epithelial sodium channel lead to bronchiectasis. 61 54
18507830 2008
11
Airway inflammation in cystic fibrosis. 61 54
18252915 2008
12
Lack of association between matrix metalloproteinase 8 promoter polymorphism and bronchiectasis in Koreans. 61 54
17728507 2007
13
Toll-like receptors 2 and 4 and innate immunity in neutrophilic asthma and idiopathic bronchiectasis. 54 61
17329561 2007
14
The role of TAP1 and TAP2 gene polymorphism in idiopathic bronchiectasis in children. 61 54
17245734 2007
15
CD4/CD8 ratio and cytokine levels of the BAL fluid in patients with bronchiectasis caused by sulfur mustard gas inhalation. 61 54
17224076 2007
16
Lack of association between the microsatellite polymorphism in intron 2 of human Toll-like receptor 2 gene and bronchiectasis among Koreans. 61 54
17207025 2007
17
Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. 54 61
17035430 2006
18
Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Asians with chronic pulmonary disease: a pilot study. 61 54
16678503 2006
19
Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. 61 54
16476120 2006
20
Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. 61 54
16297171 2005
21
[Bronchiectasis worsening by p-ANCA (bactericidal/permeability-increasing protein) positive vasculitis. A case report and review of the literature]. 54 61
16610259 2005
22
Chronic Burkholderia multivorans bronchial infection in a non-cystic fibrosis individual with mannose binding lectin deficiency. 61 54
15681508 2005
23
Indirect CFTR mutation identification by PCR/OLA anomalous electropherograms. 61 54
16379540 2005
24
CFTR mutations and polymorphisms in adults with disseminated bronchiectasis: a controversial issue. 61 54
15618592 2005
25
Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good. 61 54
15478278 2004
26
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. 61 54
15130905 2004
27
Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations? 61 54
15151509 2004
28
Atypical sinusitis in adults must lead to looking for cystic fibrosis and primary ciliary dyskinesia. 54 61
15126740 2004
29
Role of CFTR mutations in adult bronchiectasis. 61 54
15047968 2004
30
[A case of pleural effusion associated with allergic bronchopulmonary aspergillosis during a relapse of the disease]. 61 54
14727554 2003
31
The phenotypic consequences of CFTR mutations. 61 54
12940920 2003
32
Isolated idiopathic chronic pancreatitis associated with a compound heterozygosity for two mutations of the CFTR gene. 54 61
14586256 2003
33
Sputum sol neutrophil elastase activity in bronchiectasis: differential modulation by syndecan-1. 61 54
12702549 2003
34
High frequency of T9 and CFTR mutations in children with idiopathic bronchiectasis. 54 61
12843327 2003
35
[Molecular genetics principles in cystic fibrosis. An example of genetic illness in pneumology]. 61 54
14567084 2003
36
Lymphocytes in allergic bronchopulmonary aspergillosis. 54 61
12700106 2003
37
A preliminary assessment of alpha-1 antitrypsin S and Z deficiency allele frequencies in common variable immunodeficiency patients with and without bronchiectasis. 61 54
12452840 2002
38
Immunopathogenesis of allergic bronchopulmonary aspergillosis in cystic fibrosis. 61 54
15463812 2002
39
Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. 61 54
11877474 2002
40
Allergic bronchopulmonary aspergillosis: a rare cause of pleural effusion. 54 61
11844130 2001
41
Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. 61 54
11719301 2001
42
Diagnosis and treatment of allergic bronchopulmonary aspergillosis. 54 61
11560305 2001
43
Recent advances in cystic fibrosis. 54 61
11420207 2001
44
In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. 54 61
11400153 2001
45
CFTR gene mutations--including three novel nucleotide substitutions--and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. 61 54
11354633 2001
46
Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. 61 54
11120902 2001
47
Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis. 61 54
11292112 2000
48
Immunology of allergic bronchopulmonary aspergillosis. 54 61
15597669 2000
49
Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. 54 61
10669684 2000
50
Sputum elastase in steady-state bronchiectasis. 54 61
10669685 2000
Sources

Variations for Bronchiectasis

About this section

ClinVar genetic disease variations for Bronchiectasis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1):c.1154C>T (p.Thr385Met) SNV Pathogenic 144006 rs587777630 2:191851647-191851647 2:190986921-190986921
2 USP11 NM_004651.3(USP11):c.1599G>A (p.Thr533=) SNV Likely pathogenic 635007 rs777516785 X:47101903-47101903 X:47242504-47242504
3 SCNN1A NM_001038.6(SCNN1A):c.1427G>A (p.Arg476Gln) SNV Uncertain significance 598965 rs72657556 12:6458505-6458505 12:6349339-6349339
Sources

Expression for Bronchiectasis

About this section
Search GEO for disease gene expression data for Bronchiectasis.
Sources

Pathways for Bronchiectasis

About this section

Pathways related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.66 TNF TLR2 STAT1 SLPI SERPINA3 SERPINA1
2
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.54 TNF TLR2 STAT1 CXCL8 CFTR
3
IL-17 Family Signaling Pathways 64
Show member pathways
 12.18 TNF TLR2 CXCL8 CFTR
4
Defensins 65
Show member pathways
 12.17 TLR2 ELANE CTSG BPI
5
Bacterial infections in CF airways 23
Show member pathways
 11.77 TNF TLR2 STAT1 CXCL8 CFTR
6
Rheumatoid arthritis 36
11.71 TNF TLR2 CXCL8
7
Amoebiasis 36
11.68 TNF TLR2 CXCL8 CTSG
8
Matrix Metalloproteinases 1
Show member pathways
 11.62 TNF MMP8 ELANE CTSG
9
Th1 Differentiation Pathway 64
Show member pathways
 11.61 TNF TLR2 STAT1
10
Lung fibrosis 1
11.5 TNF SERPINA1 CXCL8
11
Legionellosis 36
11.43 TNF TLR2 CXCL8
12
Malaria 36
11.35 TNF TLR2 CXCL8
13
amb2 Integrin signaling 1
11.31 TNF MPO ELANE
14
Aldosterone-regulated sodium reabsorption 36
11.18 SCNN1G SCNN1B SCNN1A
15
Diuretics Pathway, Pharmacodynamics 60
11.04 SCNN1G SCNN1B SCNN1A
16
CFTR-dependent regulation of ion channels in Airway Epithelium (norm and CF) 23
10.8 SCNN1G SCNN1B SCNN1A CFTR
17
NO-dependent CFTR activation (normal and CF) 23
10.04 SCNN1G SCNN1B SCNN1A CFTR
Sources

GO Terms for Bronchiectasis

About this section

Cellular components related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.1 SLPI SERPINA3 SERPINA1 SCNN1G SCNN1B SCNN1A
2 extracellular space GO:0005615 10 TNF SLPI SERPINA3 SERPINA1 MPO MMP8
3 cell surface GO:0009986 9.91 TNF TLR2 MBL2 ELANE CTSG CFTR
4 collagen-containing extracellular matrix GO:0062023 9.7 SLPI SERPINA3 SERPINA1 MMP8 MBL2 ELANE
5 specific granule lumen GO:0035580 9.67 SLPI MMP8 ELANE BPI
6 sodium channel complex GO:0034706 9.5 SCNN1G SCNN1B SCNN1A
7 9+2 motile cilium GO:0097729 9.49 DNAI1 DNAH5
8 outer dynein arm GO:0036157 9.48 DNAI1 DNAH5
9 plasma membrane protein complex GO:0098797 9.46 SCNN1G SCNN1B
10 extracellular region GO:0005576 9.44 TNF SLPI SERPINA3 SERPINA1 MPO MMP8
11 azurophil granule lumen GO:0035578 9.35 SERPINA3 MPO ELANE CTSG BPI

Biological processes related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 TNF TLR2 SLPI CXCL8 CTSG BPI
2 defense response GO:0006952 9.84 TNF STAT1 MPO CXCL8
3 positive regulation of interleukin-6 production GO:0032755 9.79 TNF TLR2 MMP8
4 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.76 TNF TLR2 MMP8
5 extracellular matrix disassembly GO:0022617 9.75 MMP8 ELANE CTSG
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.74 TNF STAT1 ELANE
7 positive regulation of interleukin-8 production GO:0032757 9.73 TNF TLR2 ELANE
8 antimicrobial humoral response GO:0019730 9.72 ELANE CTSG BPI
9 sensory perception of taste GO:0050909 9.7 SCNN1G SCNN1B SCNN1A
10 defense response to bacterium GO:0042742 9.7 TNF SLPI MPO MBL2 ELANE CTSG
11 defense response to Gram-positive bacterium GO:0050830 9.67 TNF TLR2 MBL2 CTSG
12 acute-phase response GO:0006953 9.65 SERPINA3 SERPINA1 MBL2
13 response to lipopolysaccharide GO:0032496 9.65 TLR2 SLPI MPO ELANE CTSG
14 lipopolysaccharide-mediated signaling pathway GO:0031663 9.63 TNF TLR2 BPI
15 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF MMP8
16 defense response to fungus GO:0050832 9.61 MPO ELANE CTSG
17 positive regulation of immune response GO:0050778 9.6 ELANE CTSG
18 response to molecule of bacterial origin GO:0002237 9.59 TLR2 CXCL8
19 cellular response to aldosterone GO:1904045 9.51 SCNN1G SCNN1B
20 sodium ion homeostasis GO:0055078 9.5 SCNN1G SCNN1B SCNN1A
21 response to yeast GO:0001878 9.49 MPO ELANE
22 neutrophil degranulation GO:0043312 9.28 TLR2 SLPI SERPINA3 SERPINA1 MPO MMP8
23 multicellular organismal water homeostasis GO:0050891 9.26 SCNN1G SCNN1B SCNN1A CFTR

Molecular functions related to Bronchiectasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 WW domain binding GO:0050699 9.33 SCNN1G SCNN1B SCNN1A
2 sodium channel activity GO:0005272 9.13 SCNN1G SCNN1B SCNN1A
3 ligand-gated sodium channel activity GO:0015280 8.8 SCNN1G SCNN1B SCNN1A
Sources

Sources for Bronchiectasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....